Skip to main content

View full-text article in PMC

. 2022 Jun 18;18(1):43–48. doi: 10.17925/EE.2022.18.1.43

Table 3: Summary of STEP programme (ongoing studies)^49–53.

Trial^Ref	Clinical Trial Number	Title	Comparator	Completion date
STEP-5⁴⁹ N=304	NCT03693430	Two-year effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity	Placebo	March 2021
STEP-6⁵⁰ N=401	NCT03811574	Effect and safety of semaglutide once-weekly in East Asian subjects with overweight or obesity	Placebo	November 2020
STEP-7⁵¹ N=375	NCT04251156	Effect and safety of semaglutide 2.4 mg once-weekly on weight management in subjects with overweight or obesity (with or without T2D)	Placebo	October 2022
STEP-8⁵² N=338	NCT04074161	Effect and safety of subcutaneous semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in subjects with overweight or obesity	Liraglutide 3 mg, placebo	May 2021
SELECT⁵³ N=17,500	NCT03574597	SELECT – Semaglutide effects on cardiovascular outcomes in people with overweight or obesity Duration: 59 months	Placebo	September 2023

SELECT = Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity; STEP = Semaglutide Treatment Effect in People with obesity; T2D = type 2 diabetes.